Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sean Emery

Showing results (111-120 of 140) with videos related to

Pageof 14
Sort By:
Southern African Journal of HIV Medicine|March 24, 2018
Computational models as predictors of HIV treatment outcomes for the Phidisa cohort in South AfricaAndrew Revell, Paul Khabo, Lotty Ledwaba, et al.
Hepatology (Baltimore, Md.)|October 10, 2018
Benefit of Early versus Deferred Antiretroviral Therapy on Progression of Liver Fibrosis among People with HIV in the START Randomized TrialNila J Dharan, Jacqueline Neuhaus, Juergen K Rockstroh, et al.
Clinical Pharmacokinetics|December 31, 2015
Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 StudyLaura Dickinson, Janaki Amin, Laura Else, et al.
The Lancet. Infectious Diseases|April 17, 2015
Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study, Dianne Carey, Rebekah Puls, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 19, 2004
CD4 cell response to 3 doses of subcutaneous interleukin 2: meta-analysis of 3 Vanguard studiesRoberto C Arduino, Esteban C Nannini, Maria Rodriguez-Barradas, et al.
The Lancet. HIV|October 2, 2015
Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysisMark A Boyd, Cecilia L Moore, Jean-Michel Molina, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 29, 2004
Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infectionChaiwat Ungsedhapand, Preeyaporn Srasuebkul, Peter Cardiello, et al.
Plos One|October 10, 2015
Correction: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 InfectionJanaki Amin, Mark A Boyd, Nagalingeswaran Kumarasamy, et al.
Artificial Intelligence in Medicine|June 16, 2009
A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapyDechao Wang, Brendan Larder, Andrew Revell, et al.
Antiviral Therapy|May 17, 2007
The development of artificial neural networks to predict virological response to combination HIV therapyBrendan Larder, Dechao Wang, Andrew Revell, et al.
Pageof 14

Showing results (111-120 of 140) with videos related to

Sort By:
Pageof 14
Southern African Journal of HIV Medicine|March 24, 2018
Computational models as predictors of HIV treatment outcomes for the Phidisa cohort in South AfricaAndrew Revell, Paul Khabo, Lotty Ledwaba, et al.
Hepatology (Baltimore, Md.)|October 10, 2018
Benefit of Early versus Deferred Antiretroviral Therapy on Progression of Liver Fibrosis among People with HIV in the START Randomized TrialNila J Dharan, Jacqueline Neuhaus, Juergen K Rockstroh, et al.
Clinical Pharmacokinetics|December 31, 2015
Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 StudyLaura Dickinson, Janaki Amin, Laura Else, et al.
The Lancet. Infectious Diseases|April 17, 2015
Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study, Dianne Carey, Rebekah Puls, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 19, 2004
CD4 cell response to 3 doses of subcutaneous interleukin 2: meta-analysis of 3 Vanguard studiesRoberto C Arduino, Esteban C Nannini, Maria Rodriguez-Barradas, et al.
The Lancet. HIV|October 2, 2015
Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysisMark A Boyd, Cecilia L Moore, Jean-Michel Molina, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 29, 2004
Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infectionChaiwat Ungsedhapand, Preeyaporn Srasuebkul, Peter Cardiello, et al.
Plos One|October 10, 2015
Correction: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 InfectionJanaki Amin, Mark A Boyd, Nagalingeswaran Kumarasamy, et al.
Artificial Intelligence in Medicine|June 16, 2009
A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapyDechao Wang, Brendan Larder, Andrew Revell, et al.
Antiviral Therapy|May 17, 2007
The development of artificial neural networks to predict virological response to combination HIV therapyBrendan Larder, Dechao Wang, Andrew Revell, et al.
Pageof 14